Current Oncology Reports

, Volume 6, Issue 3, pp 237–242 | Cite as

What’s new in the field of prostate cancer chemoprevention?

  • Kanwaljit Mahal
  • Javier Hernandez
  • Joseph W. Basler
  • Ian M. Thompson
Article

Abstract

Chemoprevention trials for several malignancies are completed, planned, or underway. Prostate cancer is one of the most common forms of cancer and understandably has received considerable recent attention as a potential target for chemoprevention. This article examines chemoprevention trials for prostate cancer, including the Prostate Cancer Prevention Trial, Selenium and Vitamin E Cancer Prevention Trial, and cyclooxygenase inhibitors in the prevention of prostate cancer.

References and Recommended Reading

  1. 1.
    Cancer Facts and Figures. Atlanta, GA: American Cancer Society; 2003.Google Scholar
  2. 2.
    Tarone RE, Chu KC, Brawley OW: Implications of stagespecific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000, 11:167–170.PubMedCrossRefGoogle Scholar
  3. 3.
    Ries LAG, Eisner MP, Kosary CL, et al., eds: SEER Cancer Statistics Review, 1973–1998. Bethesda, MD: National Cancer Institute; 2002.Google Scholar
  4. 4.
    Potosky AL, Legler J, Albertsen PC, et al.: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000, 92:1582–1592.PubMedCrossRefGoogle Scholar
  5. 5.
    Clark LT: Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003, 145:387–396.PubMedCrossRefGoogle Scholar
  6. 6.
    Mehta P: Aspirin in the prophylaxis of coronary artery disease. Curr Opin Cardiol 2002, 17:552–558.PubMedCrossRefGoogle Scholar
  7. 7.
    Ford LG, Minasian LM, McCaskill-Stevens W, et al.: Prevention and early detection clinical trials: opportunities for primary care providers and their patients. CA Cancer J Clin 2003, 53:82–101.PubMedGoogle Scholar
  8. 8.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, et al.: The influence of finasteride of the development of prostate cancer. N Engl J Med 2003, 349:215–224. Summary of the important findings of the Prostate Cancer Prevention Trial. This prospective placebo-controlled trial demonstrated a 25% reduction in the incidence of prostate cancer in men taking finasteride compared with those taking placebo.PubMedCrossRefGoogle Scholar
  9. 9.
    Imperato-McGinley JL, Guerrero L, Gautier T, et al.: Steroid 5 alpha-reductase deficiency in men: an inherited form of male pseudohermaphroditism. Science 1974, 186:1213.PubMedCrossRefGoogle Scholar
  10. 10.
    Imperato-McGinley J, Gautier T, Zirinsky K, et al.: Prostate visualization studies in males homozygous and heterozygous for 5-alpha-reductase deficiency. J Clin Endocrinol Metab 1992, 75:1022.PubMedCrossRefGoogle Scholar
  11. 11.
    Gormley GJ, Stoner E, Rittmaster RS, et al.: Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990, 70:1136–1141.PubMedCrossRefGoogle Scholar
  12. 12.
    Luo J, Dunn TA, Ewing CM, et al.: Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003, 57:134–139.PubMedCrossRefGoogle Scholar
  13. 13.
    Tsukamoto S, Akaza H, Onozawa M, et al.: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998, 82:531–537.PubMedCrossRefGoogle Scholar
  14. 14.
    Algaba F, Epstein JI, Aldape HC, et al.: Assessment of prostate carcinoma in core needle biopsy: definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996, 78:376–381.PubMedCrossRefGoogle Scholar
  15. 15.
    Cote RJ, Skinner EC, Salem CE, et al.: The effect of finasteride on the prostate gland in men with elevated serum prostatespecific antigen levels. Br J Cancer 1998, 78:413–418.PubMedGoogle Scholar
  16. 16.
    Thompson IM, Klein EA, Lippman SM: Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003, 44:650–655.PubMedCrossRefGoogle Scholar
  17. 17.
    Thompson IM, Kouril M, Klein EA, et al.: The Prostate Cancer Prevention Trial: current status and lessons learned. Urology 2001, 57(Suppl 1):230–234.PubMedCrossRefGoogle Scholar
  18. 18.
    Klein EA, Thompson IM, Lippman SM, et al.: SELECT: The next prostate cancer prevention trial. J Urol 2001, 166:1311–1315.PubMedCrossRefGoogle Scholar
  19. 19.
    Yoshizawa K, Willett WC, Morris SJ, et al.: Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998, 90:1219–1224.PubMedCrossRefGoogle Scholar
  20. 20.
    Clark L, Combs G, Turnbull B, et al.: Effects of selenium supplementation for cancer prevention on patients with carcinoma of the skin. JAMA 1996, 276:1957–1963.PubMedCrossRefGoogle Scholar
  21. 21.
    Duffield-Lillico A, Dalkin BL, Reid ME, et al.: Nutritional Prevention of Cancer Study Group: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003, 91:608–612.PubMedCrossRefGoogle Scholar
  22. 22.
    Michiels C, Raes M, Toussaint O: Importance of Se-glutathione peroxidase, catalase, and CU/Zn-SOD for cell survival against oxidative stress. Free Rad Biol Med 1994, 17:235–248.PubMedCrossRefGoogle Scholar
  23. 23.
    Gasparian AV, Yao YJ, Lu J, et al.: Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 2002, 1:1079–1087.PubMedGoogle Scholar
  24. 24.
    Jiang C, Wang Z, Ganther H, Lu: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002, 1:1059–1066.PubMedGoogle Scholar
  25. 25.
    Venkateswaran V, Klotz LH, Fleshner NE: Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002, 62:2540–2545.PubMedGoogle Scholar
  26. 26.
    Heinonen OP, Albanes D, Virtano J, et al.: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440–446.PubMedCrossRefGoogle Scholar
  27. 27.
    Virtamo J, Pietinen P, Huttunen JK, et al.: ATBC Study Group: Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention followup. JAMA 2003, 290:476–485.PubMedCrossRefGoogle Scholar
  28. 28.
    The Heart Outcomes Prevention Study Investigators: Vitamin E supplements and cardiovascular events in high-risk patients. N Engl J Med 2000, 342:154–160.CrossRefGoogle Scholar
  29. 29.
    Helzlsouer KJ, Huang HY, Alberg AJ, et al.: Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000, 92:2018–2023.PubMedCrossRefGoogle Scholar
  30. 30.
    Hayes RB, Bogdanovicz JF, Schroeder FH, et al.: Serum retinol and prostate cancer. Cancer 1988, 62:2021–2026.PubMedCrossRefGoogle Scholar
  31. 31.
    Leach R, Pollock B, Basler J, et al.: Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials. Urol Clin North Am 2003, 30:227–237.PubMedCrossRefGoogle Scholar
  32. 32.
    Ni J, Chen M, Zhang Y, et al.: Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003, 300:357–363.PubMedCrossRefGoogle Scholar
  33. 33.
    Venkateswaran V, Fleshner NE, Klotz LH: Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol 2002, 168:1578–1582.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang Y, Ni J, Messing EM, et al.: Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A 2002, 99:7408–7413.PubMedCrossRefGoogle Scholar
  35. 35.
    Smith WL, De Witt DL, Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Futaki N, Takahashi S, Yokoyama M, et al.: NS-398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994, 47:55.PubMedCrossRefGoogle Scholar
  37. 37.
    Subongkot S, Frame D, Leslie W, Drajer D: Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003, 23:9–28.PubMedCrossRefGoogle Scholar
  38. 38.
    Koki AT, Leahy KM, Masferrer JL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs 1999, 8:1623–1638.PubMedCrossRefGoogle Scholar
  39. 39.
    Oshima M, Dinchuk JE, Kargman SL, et al.: Suppression of intestinal polyposis in Apc * 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803–809.PubMedCrossRefGoogle Scholar
  40. 40.
    Steinbach G, Lynch P, Phillips RKS, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946–1952.PubMedCrossRefGoogle Scholar
  41. 41.
    O’Neill GP, Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993, 30:156–160.Google Scholar
  42. 42.
    Hsu AL, Ching TT, Wang DS, Song X, et al.: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275:11397–11403.PubMedCrossRefGoogle Scholar
  43. 43.
    Liu XH, Yau S, Kirschenbaum A, Levine AC: NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res 1998, 58:4245–4249.PubMedGoogle Scholar
  44. 44.
    Liu XH, Kirschenbaum A, Yao S, Lee R, et al.: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000, 164:820–825.PubMedCrossRefGoogle Scholar
  45. 45.
    Kamijo T, Sato T, Nagatomi Y, Kitamura T: Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol 2001, 8:S35-S39.PubMedCrossRefGoogle Scholar
  46. 46.
    Gupta S, Srivastava M, Ahmad N, Bostwick DG, et al.: Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42:73–78.PubMedCrossRefGoogle Scholar
  47. 47.
    Roberts RO, Jacobson DJ, Girman CJ, et al.: A populationbased study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002, 77:219.PubMedCrossRefGoogle Scholar
  48. 48.
    Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000, 7:169–170.PubMedGoogle Scholar
  49. 49.
    Habel LA, Zhao W, Stanford JL: Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002, 13:427–434.PubMedCrossRefGoogle Scholar
  50. 50.
    Irani J, Ravery V, Pariente JL, et al.: Effect of nonsteroidal antiinflammatory agents and finasteride on prostate cancer risk. J Urol 2002, 168:1985–1988.PubMedCrossRefGoogle Scholar
  51. 51.
    Pruthi RS, Derksen JE, Gaston K: Re: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2003, 169:2304.PubMedCrossRefGoogle Scholar
  52. 52.
    Derksen JE, Pruthi RS: COX-2 inhibitors in PSA recurrent prostate cancer: a pilot study [abstract]. J Urol 2002, 167(Suppl):304.Google Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Kanwaljit Mahal
  • Javier Hernandez
    • 1
  • Joseph W. Basler
  • Ian M. Thompson
  1. 1.Division of UrologyUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations